December 2025 in “Saudi Journal of Medicine and Public Health” Pharmacists are key in choosing and guiding the safe use of topical corticosteroids for skin conditions.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, needing improvements to protect health and trust.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Post-drug syndromes are often overlooked, and better systems and education are needed to improve drug safety.
December 2025 in “International Journal of Pharmacology” iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
November 2025 in “Frontiers in Pharmacology” 64 drugs can cause hair loss, needing better monitoring and updated labels.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
September 2025 in “Journal of Cosmetic Dermatology” PRP and microneedling both effectively improve hair growth and thickness for treating hair loss.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
August 2025 in “SSP Modern Pharmacy and Medicine” Effective alopecia treatments exist, but high costs and limited access remain challenges.
July 2025 in “Journal of Ayurveda and Integrated Medical Sciences” Yashtimadhu effectively supports head and neck health with its healing and anti-inflammatory properties.
July 2025 in “Pharmaceuticals” Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
July 2025 in “Pharmaceutical Sciences & Analytical Research Journal” Herbal treatments for hair loss show promise but need more research to confirm their safety and effectiveness.
June 2025 in “Pharmacognosy Research” Dillenia indica Linn. has potential health benefits for various ailments due to its rich phytochemicals.
April 2025 in “Pharmacognosy Magazine” Compound Baqia Danshen Liniment may effectively treat vitiligo by improving skin and hair pigmentation and reducing inflammation.
February 2025 in “Advances in Therapy” The topical finasteride spray was safe and well-tolerated with stable effects.
January 2025 in “International Journal of Pharmacology” Both steroids, especially cyproterone acetate, harm quail's vital organs.
January 2025 in “International Journal of Pharmaceutical Research and Development” Herbal products are preferred for treating hair loss due to their reliability in promoting regrowth.
January 2025 in “Pharmacology & Pharmacy” Microgravity may increase drug bioavailability, potentially reaching up to 80%.
December 2024 in “Research Journal of Pharmacy and Technology” Androgenic alopecia is mainly caused by DHT, and new treatments focus on hair regeneration and aging factors.
October 2024 in “Frontiers in Pharmacology” Genetic variants can affect valproic acid's effectiveness, side effects, and levels in epilepsy treatment.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
July 2024 in “Russian Journal of Child Neurology” Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
April 2024 in “International journal of molecular sciences” Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.